MediWound Ltd. Completes Merger with 03 Life Sciences

TL;DR

MediWound and 03 Life Sciences are officially one company as of July 16, 2024, after shareholder approval.

AI Summary

On July 16, 2024, MediWound Ltd. announced the closing of its previously disclosed merger agreement with 03 Life Sciences. The transaction was approved by MediWound's shareholders on July 15, 2024. This merger combines two companies focused on innovative medical solutions.

Why It Matters

The completion of this merger signifies a strategic consolidation in the life sciences sector, potentially leading to combined resources and a broader portfolio of medical products.

Risk Assessment

Risk Level: low — The filing is a routine announcement of a completed merger, with no new financial risks or operational changes detailed.

Key Players & Entities

• MediWound Ltd. (company) — Registrant and merging entity
• 03 Life Sciences (company) — Merging entity
• July 16, 2024 (date) — Date of merger closing announcement
• July 15, 2024 (date) — Date of shareholder approval

FAQ

Filing Documents

• zk2431673.htm (6-K) — 13KB
• exhibit_99-1.htm (EX-99.1) — 19KB
• image00001.jpg (GRAPHIC) — 4KB
• 0001178913-24-002213.txt ( ) — 37KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __ EXPLANATORY NOTE On July 16, 2024, MediWound Ltd. (the "Company") issued a press release entitled "MediWound Announces 16.25 Million Funding from the European Innovation Council Accelerator Program". A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") as Exhibit 99.1. The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of senior management of the Company), is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and March 31, 2023 (Registration Nos. 333-265203 and 333-268297, respectively). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: July 16, 2024 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer EXHIBIT INDEX The following exhibit is filed as part of this Form 6-K: Exhibit Description 99.1 Press release dated July 16, 2024 entitled "MediWound Announces 16.25 Million Funding from the European Innovation Council Accelerator Program".

View Full Filing

View this 6-K filing on SEC EDGAR